This article was downloaded by: [RMIT University] On: 12 August 2015, At: 02:13 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: 5 Howick Place, London, SW1P 1WG

Current Eye Research Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/icey20

Bevacizumab for Acute Branch Retinal Vein Occlusion with Subretinal Hemorrhage a

a

a

a

a

a

Bingzhen Li , Kang Feng , Liang Han , Zhizhong Ma , Yuling Liu & Lin Zhao a

Department of Ophthalmology, Peking University Third Hospital; Peking University Eye Center; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, P.R. China Published online: 25 Jul 2015.

Click for updates To cite this article: Bingzhen Li, Kang Feng, Liang Han, Zhizhong Ma, Yuling Liu & Lin Zhao (2015) Bevacizumab for Acute Branch Retinal Vein Occlusion with Subretinal Hemorrhage, Current Eye Research, 40:7, 758-758 To link to this article: http://dx.doi.org/10.3109/02713683.2015.1004723

PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http:// www.tandfonline.com/page/terms-and-conditions

Current Eye Research, 2015; 40(7): 758 ! Informa Healthcare USA, Inc. ISSN: 0271-3683 print / 1460-2202 online DOI: 10.3109/02713683.2015.1004723

RESPONSE TO LETTER TO THE EDITOR

Bevacizumab for Acute Branch Retinal Vein Occlusion with Subretinal Hemorrhage Bingzhen Li, Kang Feng, Liang Han, Zhizhong Ma, Yuling Liu and Lin Zhao

Downloaded by [RMIT University] at 02:13 12 August 2015

Department of Ophthalmology, Peking University Third Hospital; Peking University Eye Center; Key Laboratory of Vision Loss and Restoration, Ministry of Education, Beijing, P.R. China

REFERENCES

We appreciate the opportunity to respond to the letter by Tas et al. and thank them for pointing out that one of the main predictive factors may be the duration of the macular edema until the first injection. We agree that the duration of the macular edema is a very important predictive factor. This opinion similar to that reported in several previous studies.1–3 In our study,4 we excluded macular edema of long duration (inclusion criteria for patients: duration of symptoms prior to initial examination 512 weeks), and it seems possible that if we had included longer durations, a relationship might have been found. After excluding macular edema of long duration, our findings demonstrate that the duration of symptom until initial examination is not a predictive factor associated with unfavorable outcomes (OR = 0.8, p = 0. 161) (Table 2).4 We hope this provides some clarification for the readers.

1. Jaissle GB, Szurman P, Feltgen N, Spitzer B, Pielen A, Rehak M, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2011;249:183–192. 2. Daien V, Navarre S, Fesler P, Vergely L, Villain M, Schneider C. Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 2012;22:1013–1018. 3. Yoon YH, Kim HK, Yoon HS, Kang SW, Kim JG, Park KH, et al. Improved visual outcome with early treatment in macular edema secondary to retinal vein occlusions: 6-month results of a Korean RVO study. Jpn J Ophthalmol 2014;58:146–154. 4. Zhao L, Li B, Feng K, Han L, Ma Z, Liu Y. Bevacizumab treatment for acute branch retinal vein occlusion accompanied by subretinal hemorrhage. Curr Eye Res 2014;20:1–5.

Received 28 November 2014; accepted 19 December 2014; published online 5 February 2015 Correspondence: Dr. Lin Zhao, Department of Ophthalmology, Peking University Third Hospital, Peking University Eye Center, Key Laboratory of Vision Loss and Restoration, Ministry of Education, No. 49 North Garden Road, Haidian District, Beijing 100191, P.R. China. Tel/Fax: 0086-10-82265010. E-mail: [email protected]

758

Bevacizumab for acute branch retinal vein occlusion with subretinal hemorrhage.

Bevacizumab for acute branch retinal vein occlusion with subretinal hemorrhage. - PDF Download Free
67KB Sizes 0 Downloads 15 Views